drs. L.M. (Jeanette) Braven

drs. L.M. (Jeanette) Braven

Associate Professor
drs. L.M. (Jeanette) Braven
  • Center for Translational Immunology (CTI) Research



Dr. Jeanette Leusen, received her PhD in 1995 at the University of Amsterdam, The Netherlands. She became associate professor and head of the immunotherapy group of the University Medical Center in Utrecht in 2006, and head of the UMAB facility in 2012. She has co-authored more than 120 publications in peer-reviewed journals and is inventor on 10 patent applications. Her group of 24 FTE works on the mechanism of action of therapeutic antibodies, with a special interest in IgA as a novel class of antibody for the treatment of both malignant as infectious disease.


See her research group webpage here >

Side Activities

Dr Leusen is the scientific founder of TigaTx in 2018, a spin-off company on engineered IgA as therapeutic antibody in oncology.

Dr Leusen is senior editor of several Immunology/cancer journals and was organizer of the FASEB meeting on Immunoreceptors of 2014 and 2016, and was vice chair of the Gordon Research Conference on Antibody Biology and Engineering in 2018, and main chair in 2022,

Fellowship and Awards

Dr Leusen holds several grants from Health Holland, KWF, Villa Joep! and industry.

Research Output (121)

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure

Wachsmann Tassilo L A, Wouters Anne K, Remst Dennis F G, Hagedoorn Renate S, Meeuwsen Miranda H, van Diest Eline, Leusen Jeanette, Kuball Jürgen, Falkenburg J H Frederik, Heemskerk Mirjam H M 2022, In: OncoImmunology. 11

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma

Evers Mitchell, Stip Marjolein, Keller Kaylee, Willemen Hanneke, Nederend Maaike, Jansen Marco, Chan Chilam, Budding Kevin, Nierkens Stefan, Valerius Thomas, Meyer-Wentrup Friederike, Eijkelkamp Niels, Leusen Jeanette 29 Oct 2021, In: Journal for ImmunoTherapy of Cancer. 9 , p. 1-14

The selection of variable regions affects effector mechanisms of IgA antibodies against CD20

Evers Mitchell, Rösner Thies, Duenkel Anna, Jansen J H Marco Marco, Baumann Niklas, Ten Broeke Toine, Nederend Maaike, Eichholz Klara, Klausz Katja, Reiding Karli, Schewe Denis M M, Kellner Christian, Peipp Matthias, Leusen Jeanette H W, Valerius Thomas 15 Sep 2021, In: Blood Advances. 5 , p. 3807-3820 14 p.

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

Hamdan Firas, Ylösmäki Erkko, Chiaro Jacopo, Giannoula Yvonne, Long Maeve, Fusciello Manlio, Feola Sara, Martins Beatriz, Feodoroff Michaela, Antignani Gabriella, Russo Salvatore, Kari Otto, Lee Moon, Järvinen Petrus, Nisen Harry, Kreutzman Anna, Leusen Jeanette, Mustjoki Satu, McWilliams Thomas G, Grönholm Mikaela, Cerullo Vincenzo 6 Aug 2021, In: Journal for ImmunoTherapy of Cancer. 9

Synergestic Tumor-Killing Effect by Cross-Hybrid IgGA Fc

Hamdan Firas, Ylosmaki Erkko, Chiaro Jacopo, Giannoula Yvonne, Long Maeve, Fusciello Manlio, Feola Sara, Martins Beatriz, Feodoroff Michaela, Antignani Gabriella, Kari Otto, Lee Moon Hee, Jarvinen Petrus, Nisen Harry, Kreutzman Anna, Leusen Jeanette, Mustjoki Satu, McWilliams Thomas, Gronholm Mikaela, Cerullo Vincenzo 27 Apr 2021, In: Molecular Therapy. 29 , p. 322-322

Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms

Walbaum Stefan, Ambrosy Benjamin, Schütz Paula, Bachg Anne C., Horsthemke Markus, Leusen Jeanette H.W., Mócsai Attila, Hanley Peter J. 1 Jan 2021, In: Journal of Biological Chemistry. 296 , p. 1-22

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo

Mester Simone, Evers Mitchell, Meyer Saskia, Nilsen Jeannette, Greiff Victor, Sandlie Inger, Leusen Jeanette, Andersen Jan Terje 1 Jan 2021, In: mAbs. 13 , p. 1-14

Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions

Baumann Niklas, Roesner Thies, Jansen J. H. Marco, Chan Chilam, Eichholz Klara Marie, Klausz Katja, Winterberg Dorothee, Mueller Kristina, Humpe Andreas, Burger Renate, Peipp Matthias, Schewe Denis M., Kellner Christian, Leusen Jeanette H. W., Valerius Thomas 2021, In: CANCER SCIENCE. 112 , p. 3029-3040 12 p.

Bovine IgG Prevents Experimental Infection With RSV and Facilitates Human T Cell Responses to RSV

Nederend Maaike, van Stigt Arthur H., Jansen J. H.Marco, Jacobino Shamir R., Brugman Sylvia, de Haan Cornelis A.M., Bont Louis J., van Neerven R. J.Joost, Leusen Jeanette H.W. 6 Aug 2020, In: Frontiers in Immunology. 11 , p. 1-9

gamma 9 delta 2T cell diversity and the receptor interface with tumor cells

Vyborova Anna, Beringer Dennis X, Fasci Domenico, Karaiskaki Froso, van Diest Eline, Kramer Lovro, de Haas Aram, Sanders Jasper, Janssen Anke, Straetemans Trudy, Olive Daniel, Leusen Jeanette Hw, Boutin Lola, Nedellec Steven, Schwartz Samantha L, Wester Michael J, Lidke Keith A, Scotet Emmanuel, Lidke Diane, Heck Albert Jr, Sebestyen Zsolt, Kuball Jurgen 2 Jun 2020, In: Journal of Clinical Investigation. 130 , p. 4637-4651 15 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet